Systemic methotrexate for the treatment of psoriasis

Oriol Yélamos, Lluís Puig

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)


© 2015 Informa UK, Ltd. In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
Original languageEnglish
Pages (from-to)553-563
JournalExpert Review of Clinical Immunology
Issue number5
Publication statusPublished - 1 May 2015


  • Adenosine
  • Dihydrofolate reductase inhibitor
  • Folic acid
  • Methotrexate
  • Methotrexate polyglutamates
  • Pharmacogenetics
  • Psoriasis


Dive into the research topics of 'Systemic methotrexate for the treatment of psoriasis'. Together they form a unique fingerprint.

Cite this